RT Journal Article
SR Electronic
T1 Functional alteration of innate T cells in critically ill Covid-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.03.20089300
DO 10.1101/2020.05.03.20089300
A1 Jouan, Youenn
A1 Guillon, Antoine
A1 Gonzalez, Loïc
A1 Perez, Yonatan
A1 Ehrmann, Stephan
A1 Ferreira, Marion
A1 Daix, Thomas
A1 Jeannet, Robin
A1 François, Bruno
A1 Dequin, Pierre-François
A1 Si-Tahar, Mustapha
A1 Baranek, Thomas
A1 Paget, Christophe
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.03.20089300.abstract
AB Covid-19 can induce lung infection ranging from mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key feature in ARDS pathophysiology. However, cellular actors in Covid-19-driven ARDS are poorly understood. Here, we dynamically analyzed the biology of innate T cells, a heterogeneous class (MAIT, γδT and iNKT cells) of T lymphocytes, presenting potent anti-infective and regulatory functions. Patients presented a compartmentalized lung inflammation paralleled with a limited systemic inflammation. Circulating innate T cells of critically ill Covid-19 patients presented a profound and persistent phenotypic and functional alteration. Highly activated innate T cells were detected in airways of patients suggesting a recruitment to the inflamed site and a potential contribution in the regulation of the local inflammation. Finally, the expression of the CD69 activation marker on blood iNKT and MAIT cells at inclusion was predictive of disease severity. Thus, patients present an altered innate T cell biology that may account for the dysregulated immune response observed in Covid-19-related acute respiratory distress syndrome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03379207Funding StatementThis work was supported by the Inserm, CHRU Tours, University of Tours, the Agence Nationale de la Recherche “JCJC program” (ANR-19-325 CE15-0032-01) and by the Fondation du Souffle, with the “Fond de recherche en Santé Respiratoire”.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request to christophe.paget{at}inserm.fr